Identification of an activin-follistatin growth modulatory system in the human prostate: Secretion and biological activity in primary cultures of prostatic epithelial cells

Journal of Urology

Volumn 161, Issue 4, 1999, Pages 1378-1384

  Wang, Qifa ^a   Tabatabaei, Shahin ^a   Planz, Bernhard ^a   Lin, Chi Wei ^a   Sluss, Patrick M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Activin; Follistatin; Prostate

Indexed keywords

ACTIVIN A; FOLLISTATIN;

ARTICLE; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE SECRETION; REGULATORY MECHANISM;

EID: 0032862565     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61687-2     Document Type: Article

References (40)

1. Mather, J. P., Moore, A. and Li, R. H.: Activins, inhibins, and follistatins: further thoughts on a growing family of regulators. Proc. Soc. Exp. Biol. Med., 215: 209, 1997.
2. Risbridger, G. P., Thomas, T., Gurusinghe, C. J. and McFarlane, J. R.: Inhibin-related proteins in rat prostate. J. Endocrinol., 149: 93, 1996.
3. Ying, S. Y., Zhang, Z. F. and Guo, H. A.: Expression and localization of inhibin/activin subunits and activin receptors in the normal rat prostate. Life Sci., 60: 397, 1997.
4. Feng, Z. and Madigan, M. B.: Expression of type II activin receptor genes in the male and female reproductive tissues of the rat. Endocrinology, 132: 2593, 1993.
5. Boitani, C., Stefanini, M., Fragale, A. and Morena, A.: Activin stimulates Sertoli cell proliferation in a defined period of rat testis development. Endocrinology, 136: 5438, 1995.
6. Schubert, D., Kimura, H. and LaCorbiere, M.: Activin is a nerve cell survival molecule. Nature, 344: 868, 1990.
7. Gonzalez-Manchon, C. and Vale, W. W.: Activin-A, inhibin and transforming growth factor-β modulate growth of two gonadal cell lines. Endocrinology, 125: 1666, 1989.
8. Liu, Q. Y., Niranjan, B., Gomes, P., Gomm, J. J., Davies, D. R., Coombes, R. C. and Buluwela, L.: Inhibitory effects of activin on the growth and morphogenesis of primary and transformed mammary epithelial cells. Cancer Res., 56: 1155, 1996.
9. Nishihara, T., Okahashi, N. and Ueda, N.: Activin A induces apoptotic cell death. Biochem. Biophys. Res. Commun., 197: 985, 1993.
10. Tan, J., Sharief, Y., Hamil, K. G., Gregory, C. W., deVere-White, R. W., Pretlow, T. G., Harris, S. E., Wilson, E. M., Mohler, J. L. and French, F. S.: Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol., 11: 450, 1997.
11. Wang, Q. F., Tilly, K. I., Tilly, J. L., Preffer, F., Schneyer, A. L., Crowley, W. F., Jr. and Sluss, P. M.: Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LnCaP. Endocrinology, 137: 5476, 1996.
12. de Winter, J. P., ten Dijke, P., de Vries, C. J. M., van Achterverg, T. A. E., Sugino, H., de Waele, P., Huylebroeck, D., Verschueren, K. and van den Eijnden-van Raaij, A. J. M.: Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors. Mol. Cell Endocrinol., 116: 105, 1996.
13. Inouye, S., Guo, Y., DePaulo, L. V., Shimonaka, M., Ling, N. and Shimasaki, S.: Recombinant expression of human follistatin with 315 and 288 amino acids: chemical and biological comparison with native porcine follistatin. Endocrinology, 129: 815, 1991.
14. Michel, U., Albiston, A. and Findlay, J. K.: Rat follistatin: Gonadal and extragonadal expression and evidence for alternative splicing. Biochem. Biophys. Res. Commun., 173: 401, 1990.
15. Shimasaki, S., Koga, M., Esch, F., Mercado, M., Cooksey, K., Koba, A. and Ling, N.: Porcine follistatin gene structure supports two forms of mature follistatin produced by alternative splicing. Biochem. Biophys. Res. Commun., 152: 717, 1988.
16. Mathews, L. S.: Activin receptors and cellular signaling by the receptor serine kinase family. Endocrine Rev., 15: 310, 1994.
17. DePaulo, L. V., Bicsak, T. A., Erickson, G. F., Shimasaki, S. and Ling, N.: Follistatin and activin: a potential intrinsic regulatory system within diverse tissues. Proc. Soc. Exp. Biol. Med., 198: 500, 1991.
18. Matzuk, M. M.: Functional analysis of mammalian members of the transforming growth factor-beta superfamily. Trends Endocrinol. Metab., 6: 120, 1995.
19. Bates, Y., Zhang, Z. and Ying, S. Y.: Expression of activins and activin receptor messenger RNAs in LNCaP cells, a human prostatic adenocarcinoma cell line. Int. J. Oncol., 6: 1185, 1995.
20. van Schaik, R. H. N., Wierikx, C. D. J., Timmerman, M. A., Oomen, M. H. A., van Steenbrugge, G. J. and deJong, F. H.: Activin and activin receptors in human prostatic carcinoma. Urol. Res., 23: 263, 1995.
21. Vale, W. W., Bilezikjian, L. M., Rivier, C., Knobil, E. and Neill, J. D.: The Physiology of Reproduction. 2nd ed. New York: Raven Press, pp. 1861-78, 1994.
22. Petraglia, F.: Inhibin, activin, follistatin in the human placenta - a new family of regulatory proteins. Placenta, 18: 3, 1997.
23. Kozian, D. H., Ziche, M. and Augustin, H. G.: The activin-binding protein follistatin regulates autocrine endothelial cell activity and induces angiogenesis. Lab. Invest., 76: 267, 1997.
24. deJong, F. H., de Winter, J. P., Wesseling, J. G., Timmerman, M. A., van Genesen, S., van den Eijinden-van Raaij, A. J. M. and van Zoelen, E. J. J.: Inhibin subunits, follistatin and activin receptors in the human teratocarcinoma cell line tera-2. Biochem. Biophys. Res. Commun., 192: 1334, 1993.
25. DiSimone, N., Crowley, W. F., Jr., Wang, Q. F., Sluss, P. M. and Schneyer, A. L.: Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology, 137: 486, 1996.
26. Wang, Q. F., Khoury, R. H., Smith, P. C., McConnell, D. S., Padmanabhan, V., Midgley, A. R., Schneyer, A. L., Crowley, W. F., Jr. and Sluss, P. M.: A two-site monoclonal antibody immunoradiometric assay for human follistatin: Secretion by a human ovarian teratocarcinoma-derived cell line (PA-1). J. Clin. Endocrinol. Metab., 81: 1434, 1996.
27. Kato, M., Sato, H., Tsukada, T., Ikawa, Y., Aizawa, S. and Nagayoshi, M.: A follistatin-like gene, mac25, may act as a growth suppressor of osteosarcoma cells. Oncogene, 12: 1361, 1996.
28. Wang, Q. F., Schneyer. A. L., Crowley, W. F., Jr. and Sluss, P. M.: Overexpression of follistatin by a human prostate cancer cell line, PC-3 (Abstract). Ann. Meeting Endocr. Soc., 1996.
29. van Steenbrugge, G. J., van Uffelen, C. J. C., Bolt, J. and Schroder, F. H.: The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen-sensitivity. J. Steroid Biochem. Mol. Biol., 40: 207, 1991.
30. Soto, A. M., Lin, T., Sakabe, K., Olea, N., Damassa, D. A. and Sonnenschein, C.: Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response. Oncol. Res., 7: 545, 1995.
31. Knabbe, C., Kellner, U., Schmahl, M. and Voigt, K. D.: Growth factors in human prostate cancer cells: implications for an improved treatment of prostate cancer. J. Steroid Biochem. Mol. Biol., 40: 185, 1991.
32. Janssen, T., Darro, F., Petein, M., Raviv, G., Pasteels, J. L., Kiss, R. and Schulmann, C. C.: In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer, 77: 144, 1996.
33. McConnell, D. S., Wang, Q. F., Sluss, P. M., Bolf, N., Khoury, R. H., Schneyer, A. L., Midgley, A. R., Reame, N. E., Crowley, W. F., Jr. and Padmanabhan, V.: A two-site chemiluminescent assay for activin-free follistatin reveals that most follistatin circulating in men and normal cycling women is in an activin-bound state. J. Clin. Endocrinol. Metab., 83: 851, 1998.
34. Knight, P. G., Muttukrishna, S. and Groome, N. P.: Development and application of a two-site enzyme immunoassay for the determination of "total" activin-A concentrations in serum and follicular fluid. J. Endocrinol., 148: 267, 1996.
35. Muttukrishna, S., Fowler, P. A., George, L., Groome, N. P. and Knight, P. G.: Changes in peripheral serum levels of "total" activin A during the human menstrual cycle and pregnancy. Clin. Endocrinol. Metab., 81: 1, 1996.
36. Schneyer, A. L., Rzucidlo, D. A., Sluss, P. M. and Crowley, W. F., Jr.: Characterization of unique binding kinetics of follistatin and activin or inhibin in serum. Endocrinology, 135: 667, 1994.
37. Zhang, Z., Ying, C. and Bates, Y.: Expression of activin and activin receptors in the prostate cancer cell lines LnCAP and DU145 (Abstract). Ann. Meeting Endocr. Soc., 1-363, 1995.
38. 125I-recombinant human activin A to the female rat brain. Endocrinology, 131: 3117, 1992.
39. Armbruster, D. A., Hubster, E. C., Kaufman, M. S. and Ramon, M. K.: Cloned enzyme donor immunoassay (CEDIA) for drugs-of-abuse screening. Clin. Chem., 41: 92, 1995.
40. Alexander, J. M., Jameson, J. L., Bikkal, H. A., Schwall, R. H. and Klibanski, A.: The effects of activin on follicle-stimulating hormone secretion and biosynthesis in human glycoprotein hormone-producing pituitary adenomas. J. Clin. Endocrinol. Metab., 72: 1261, 1991.